Review Article: The Comparison of Effectiveness and Side Effects of Pembrolizumab in Combination with Chemotherapy versus Single Chemotherapy in the Treatment of Non-Small Cell Lung Cancer (NSCLC)
Article Sidebar
Main Article Content
Page: 1336-1354
Abstract
This review article aims to compare the effectiveness and side effects of pembrolizumab combined with chemotherapy versus chemotherapy alone in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). A systematic review was conducted using literature published between 2015 and 2024. Relevant studies were identified through databases such as Google Scholar, using keywords like "Pembrolizumab," "Side Effects," "Effectiveness," "Overall Survival (OS)," and "Progression-Free Survival (PFS)." The results showed that pembrolizumab combined with chemotherapy significantly improved Overall Survival (OS) and Progression-Free Survival (PFS) compared to chemotherapy alone. However, this combination therapy was associated with a higher frequency of side effects, such as pneumonitis and hypothyroidism. In conclusion, pembrolizumab combined with chemotherapy offers superior efficacy in prolonging survival and controlling disease progression in advanced NSCLC. However, its use requires careful patient selection and close monitoring of toxicity. These findings support pembrolizumab as a promising first-line therapy for advanced NSCLC.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl) 2023;136:1583–90. https://doi.org/10.1097/CM9.0000000000002529. DOI: https://doi.org/10.1097/CM9.0000000000002529
Wan N, Zhang T tian, Hua S hua, Lu Z luo, Ji B, Li L xia, Lu L qing, Huang W jie, Jiang J, Li J. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. Cancer Med 2020;9:1683–93. https://doi.org/10.1002/cam4.2793.
Wan N, Zhang T tian, Hua S hua, Lu Z luo, Ji B, Li L xia, Lu L qing, Huang W jie, Jiang J, Li J. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. Cancer Med 2020;9:1683–93. https://doi.org/10.1002/cam4.2793. DOI: https://doi.org/10.1002/cam4.2793
Attili I, Valenza C, Santoro C, Antonarelli G, Trillo Aliaga P, Del Signore E, Catania C, Spitaleri G, Passaro A, de Marinis F. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%. Front Oncol 2022;12. https://doi.org/10.3389/fonc.2022.980765. DOI: https://doi.org/10.3389/fonc.2022.980765
Sudarjat H. Computing Bibliometric Analysis with Mapping Visualization using VOSviewer on “Pharmacy” and “Special Needs” Research Data in 2017-2021. ASEAN Journal of Community and Special Needs Education 2023;2:1–8.
Irfan M, Septiadi Y, Rivandra MA, Rakhmawati NA. Analisis Bibliometrik Publikasi tentang ChatGPT. Journal Information Engineering and Educational Technology 2023;07.
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee S-M, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O’Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C. Tracking the Evolution of Non–Small-Cell Lung Cancer. New England Journal of Medicine 2017;376:2109–21. https://doi.org/10.1056/nejmoa1616288. DOI: https://doi.org/10.1056/NEJMoa1616288
Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016;893:1–19. https://doi.org/10.1007/978-3-319-24223-1_1. DOI: https://doi.org/10.1007/978-3-319-24223-1_1
Vinay Kumar. Robbins Basic Pathology. 8th ed. Philadelphia: Saunders Elsevier; 2007.
Andayani N, Julisafrida L. Peranan Immunoterapi Pada Kanker Paru. Jurnal Kedokteran Syiah Kuala 2020;20. https://doi.org/10.24815/jks.v20i2.18499. DOI: https://doi.org/10.24815/jks.v20i2.18499
Abul K. Abbas, Andrew H. Lichtman, Shiv Pillai. Basic Immunology: Functions and Disorders of the Immune System. 5th ed. Philadelphia: Elsevier; 2015.
Wang D, Gilbert J, Kim YJ. Immunotherapy: Who Is Eligible? Otolaryngol Clin North Am 2017;50:867–74. https://doi.org/10.1016/j.otc.2017.04.006. DOI: https://doi.org/10.1016/j.otc.2017.04.006
Kudo M. Pembrolizumab for the treatment of hepatocellular carcinoma. Liver Cancer 2019;8:143–54. https://doi.org/10.1159/000500143. DOI: https://doi.org/10.1159/000500143
Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017;24. https://doi.org/10.1186/s12929-017-0329-9. DOI: https://doi.org/10.1186/s12929-017-0329-9
Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat Rev 2018;62:39–49. https://doi.org/10.1016/j.ctrv.2017.10.002. DOI: https://doi.org/10.1016/j.ctrv.2017.10.002
Rachma B, Savitri M, Sutanto H. Cardiotoxicity in platinum-based chemotherapy: Mechanisms, manifestations, and management. Cancer Pathogenesis and Therapy 2024. https://doi.org/10.1016/j.cpt.2024.04.004. DOI: https://doi.org/10.1016/j.cpt.2024.04.004
Tomasini P, Barlesi F, Mascaux C, Greillier L. Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: Latest evidence about its extended use and outcomes. Ther Adv Med Oncol 2016;8:198–208. https://doi.org/10.1177/1758834016644155. DOI: https://doi.org/10.1177/1758834016644155
Villaruz LC, Socinski MA. Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. Eur J Cancer 2016;56:162–71. https://doi.org/10.1016/j.ejca.2015.12.022. DOI: https://doi.org/10.1016/j.ejca.2015.12.022
Gadgeel S, Delvys Rodríguez-Abreu ;, Speranza G, Esteban E, Felip E, Manuel ;, Omine D´, Hui R, Hochmair MJ, Clingan P, Steven ;, Powell F, Susanna ;, Cheng Y-S, Bischoff HG, Peled ; Nir, Grossi F, Ross ;, Jennens R, Reck ; Martin, Garon ; Edward B, Novello S, Belén Rubio-Viqueira ;, Boyer ; Michael, Kurata ; Takayasu, Jhanelle ;, Gray E, Yang J, Tuba Bas ;, Pietanza ; M Catherine, Garassino MC. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. vol. 38. 2020. DOI: https://doi.org/10.1200/JCO.19.03136
Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JCH, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist L V., Saraf S, Zhao B, Piperdi B, Langer CJ. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology 2021;16:162–8. https://doi.org/10.1016/j.jtho.2020.09.015. DOI: https://doi.org/10.1016/j.jtho.2020.09.015
Borghaei H, Langer CJ, Paz-Ares L, Rodríguez-Abreu D, Halmos B, Garassino MC, Houghton B, Kurata T, Cheng Y, Lin J, Pietanza MC, Piperdi B, Gadgeel SM. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer 2020;126:4867–77. https://doi.org/10.1002/cncr.33142. DOI: https://doi.org/10.1002/cncr.33142
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Haratani K, Itoh S, Uemura T, Morinaga R, Takahama T, Nakashima K, Tachihara M, Saito G, Tanizaki J, Otsubo K, Ikeda S, Matsumoto H, Hara S, Hata A, Masuda T, Yamamoto N. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. JTO Clin Res Rep 2022;3. https://doi.org/10.1016/j.jtocrr.2021.100265. DOI: https://doi.org/10.1016/j.jtocrr.2021.100265
Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, Hermes B, Cicin I, Medgyasszay B, Rodríguez-Cid J, Okamoto I, Lee SS, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, vol. 15, Elsevier Inc.; 2020, p. 1657–69. https://doi.org/10.1016/j.jtho.2020.06.015. DOI: https://doi.org/10.1016/j.jtho.2020.06.015
Chen M, Xu Y, Zhao J, Liu X, Liu X, Zhang D, Shi Y, Zhang L, Zhong W, Wang M. Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non–small-Cell Lung Cancer Patients. Clin Lung Cancer 2023;24:278–86. https://doi.org/10.1016/j.cllc.2022.12.003. DOI: https://doi.org/10.1016/j.cllc.2022.12.003
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY-S, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine 2018;378:2078–92. https://doi.org/10.1056/nejmoa1801005. DOI: https://doi.org/10.1056/NEJMoa1801005
Powell SF, Rodríguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG, Rodríguez-Cid J, Kowalski DM, Cheng Y, Kurata T, Awad MM, Lin J, Zhao B, Pietanza MC, Piperdi B, Garassino MC. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. Journal of Thoracic Oncology, vol. 16, Elsevier Inc.; 2021, p. 1883–92. https://doi.org/10.1016/j.jtho.2021.06.020. DOI: https://doi.org/10.1016/j.jtho.2021.06.020
Zhou Y, Lin Z, Zhang X, Chen C, Zhao H, Hong S, Zhang L. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: Pembrolizumab or pembrolizumab plus chemotherapy. J Immunother Cancer 2019;7. https://doi.org/10.1186/s40425-019-0600-6. DOI: https://doi.org/10.1186/s40425-019-0600-6
Haanen JBAG, Carbonnel F, Robret C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv119-iv142. DOI: https://doi.org/10.1093/annonc/mdx225